People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pear Therapeutics, Inc. | — | Pharma | Series D+ | $254.8M | $4.1B | 2017 |
Christopher Guiffre at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Guiffre on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| Timothy Petersen | 1 | 9 |
| Andrew J. Schwab | 1 | 7 |
| Corey McCann | 1 | 5 |
| Elena Viboch | 1 | 4 |
| Zack Lynch | 1 | 2 |
| Alex Waldron | 1 | 2 |
| ANTOUN NABHAN | 1 | 2 |
| Julia Strandberg | 1 | 1 |
| Yuri Maricich | 1 | 1 |
| Ronan O'Brien | 1 | 1 |
| Jeremy Gilbert | 1 | 1 |
| Zack J. Lynch | 1 | 1 |
| Hongjie Hu | 1 | 1 |
| Tim J. Petersen | 1 | 1 |
| Nancy Schlichting | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.